A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections. The drug, called enlicitide, slashes levels ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in the cardiovascular field. As this year’s Scientific Sessions of the American ...

Amgen announced new Repatha trial results from its landmark Phase 3 VESALIUS-CV study. The data showed Repatha (evolocumab) cut the risk of a first heart attack by 36%. It also reduced the risk of ...

The daily pills are designed for use among those whose high cholesterol is not reaching healthy targets despite taking other medications. Thana Prasongsin via Getty Images An experimental pill ...

The addition of Repatha to standard treatment, statins or other low-density lipoprotein (LDL-C) lowering treatments reduced major adverse cardiovascular events (MACE)— death, heart attack or ischemic ...

Merck's new pill, enlicitide, and Amgen's longtime Repatha shot are showing heart attack risk-lowering potential, and researchers have made progress on the gene-editing front. The New York Times: New ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower ...